An open label, pilot study to determine the effect of in-centre and at-home administration intra-cavernosal injections of Invicorp on male Erectile Dysfunction (ED) post radical prostatectomy

开始日期2022-08-22

申办/合作机构-

100 项与阿肽地尔/甲磺酸酚妥拉明相关的临床结果

登录后查看更多信息

100 项与阿肽地尔/甲磺酸酚妥拉明相关的转化医学

登录后查看更多信息

100 项与阿肽地尔/甲磺酸酚妥拉明相关的专利（医药）

登录后查看更多信息

项与阿肽地尔/甲磺酸酚妥拉明相关的文献（医药）

2010-09-01·BJU International2区 · 医学

The anatomy of drug development: Invicorp®, a product before its time

2区 · 医学

Article

作者: Wyllie, Michael G

2008-10-01·BJU International

Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction.

Review

作者: Wyllie, Michael G. ; Dinsmore, W. Wallace

Erectile dysfunction (ED) is becoming an increasingly common problem and although oral therapies offer first-line treatment for many men, they are contraindicated or ineffective in substantial groups of patients. Intracavernosal injection (ICI) therapy is the most effective nonsurgical treatment for ED and offers an effective alternative to oral therapy. Sufficient arterial blood supply and a functional veno-occlusive mechanism are prerequisites in the attainment and maintenance of a functional erection. Invicorp (Plethora Solutions, London, UK) is a combination of vasoactive intestinal polypeptide (VIP) 25 microg and phentolamine mesylate 1 or 2 mg for ICI in the management of moderate to severe ED. The two active components have complementary modes of action; VIP has a potent effect on the veno-occlusive mechanism, but little effect on arterial inflow, whereas phentolamine increases arterial blood flow with no effect on the veno-occlusive mechanism. Clinical studies showed that Invicorp is effective in >or=80% of men with ED, including those who have failed to respond to other therapies and, unlike existing intracavernosal therapies, is associated with a very low incidence of penile pain and virtually negligible risk of priapism. We estimate that there are >5.9 million men in the USA alone for whom oral ED drugs are not a viable treatment option, and for whom Invicorp might offer a safe and effective alternative.

2000-04-01·IDrugs : the investigational drugs journal

European Society for Impotence Research--third meeting. 30 January-2 February 2000, Barcelona, Spain.

Article

作者: Adeniyi, A

The role of sildenafil (Viagra; Pfizer Inc) in a variety of indications, including spinal cord injury following prostatectomy, was presented. Results obtained by comparing different therapies were also presented. The role of sildenafil in long-term users of intracavernous and intra-urethral therapy was presented by at least two groups with interesting results. Conversely, a presentation on the role of intracavernosal therapy in patients who had failed to respond to sildenafil revealed thought provoking-findings. The anticipation by delegates of an opportunity to preview new therapy was also satisfied, at least in part, with presentations on Invicorp (Senetek plc), sublingual apomorphine (TAP Pharmaceuticals Inc), BAY-38-9456 (Bayer Yakuhin Ltd), and a yohimbine/arginine combination. MUSE therapy (VIVUS Inc) was also revisited. The various presentations on the treatment of erectile dysfunction revealed a trend towards a more practical approach.

100 项与阿肽地尔/甲磺酸酚妥拉明相关的药物交易

登录后查看更多信息